127 related articles for article (PubMed ID: 9644287)
1. Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results.
Cahill LM; Murdoch BE; Theodoros DG; Triggs EJ; Charles BG; Yao AA
Motor Control; 1998 Apr; 2(2):161-72. PubMed ID: 9644287
[TBL] [Abstract][Full Text] [Related]
2. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
3. Effects of Levodopa on Vowel Articulation in Patients with Parkinson's Disease.
Okada Y; Murata M; Toda T
Kobe J Med Sci; 2015 Apr; 61(5):E144-54. PubMed ID: 27363398
[TBL] [Abstract][Full Text] [Related]
4. Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
Pinho P; Monteiro L; Soares MFP; Tourinho L; Melo A; Nóbrega AC
Codas; 2018 Oct; 30(5):e20170200. PubMed ID: 30304100
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
[TBL] [Abstract][Full Text] [Related]
6. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
[TBL] [Abstract][Full Text] [Related]
7. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
8. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.
Skodda S; Grönheit W; Schlegel U
J Voice; 2011 Jul; 25(4):e199-205. PubMed ID: 21051196
[TBL] [Abstract][Full Text] [Related]
9. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P
Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751
[TBL] [Abstract][Full Text] [Related]
10. Glottographic measures before and after levodopa treatment in Parkinson's disease.
Jiang J; Lin E; Wang J; Hanson DG
Laryngoscope; 1999 Aug; 109(8):1287-94. PubMed ID: 10443835
[TBL] [Abstract][Full Text] [Related]
11. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
Walker RW; Howells AR; Gray WK
Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
[TBL] [Abstract][Full Text] [Related]
12. Bilateral subthalamic stimulation effects on oral force control in Parkinson's disease.
Pinto S; Gentil M; Fraix V; Benabid AL; Pollak P
J Neurol; 2003 Feb; 250(2):179-87. PubMed ID: 12574948
[TBL] [Abstract][Full Text] [Related]
13. Mood response to levodopa infusion in early Parkinson's disease.
Maricle RA; Valentine RJ; Carter J; Nutt JG
Neurology; 1998 Jun; 50(6):1890-2. PubMed ID: 9633754
[TBL] [Abstract][Full Text] [Related]
14. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
15. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
Azevedo LL; Souza IS; Oliveira PM; Cardoso F
Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
[TBL] [Abstract][Full Text] [Related]
16. Prosody and levodopa in Parkinson's disease.
Azevedo LL; Reis CA; Souza IS; Cardoso FE
Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
[TBL] [Abstract][Full Text] [Related]
17. Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.
Gentil M; Tournier CL; Pollak P; Benabid AL
Eur Neurol; 1999; 42(3):136-40. PubMed ID: 10529538
[TBL] [Abstract][Full Text] [Related]
18. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
19. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
20. Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.
Rocchi L; Chiari L; Horak FB
J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):267-74. PubMed ID: 12185157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
